23andMe Investor Presentation Deck
February 2022, 63 slides
  1. 23andMe
  2. Related Decks
  3. Investor Presentation Decks
investor presentation | 23andMe
disclaimer | 23andMe
behind every data point is a human being | 23andMe
our mission is to help people access understand and benefit from the human genome | 23andMe
the system is | 23andMe
consumer scale and empowerment is the key to disrupting | 23andMe
we pioneered digital to empower customers with affordable direct access | 23andMe
providing customers with key actionable insights | 23andMe
transforming with genetic | 23andMe
unlocking the genetic code creates the opportunity to revolutionize the diagnosis prevention and treatment of most if not all human disease a is a data problem a very big data problem billion | 23andMe
we are redefining with data at scale | 23andMe
consumer powered flywheel to research products as | 23andMe
our ancestry service | 23andMe
how ancestry matters in connection to your health meet as related | 23andMe
our health service | 23andMe
a meaningful engaging and fun experience | 23andMe
| 23andMe
transforming with genetics based primary at scale | 23andMe
impact of different factors on risk of premature death we have a significant opportunity to improve people health death | 23andMe
genetic data helps drive behavior change | 23andMe
opportunity for personalized at scale a a | 23andMe
opportunity to deliver genetics based primary at scale testing | 23andMe
what is genetics based primary health predispositions carrier status wellness | 23andMe
is fully integrated with a broad service offering | 23andMe
the future primary care complete | 23andMe
transforming therapeutic development with the | 23andMe
limited use of genetic data and lack of patient engagement constrain productivity drug development is inefficient | 23andMe
potential to more efficiently develop novel therapeutics by power need and speed years average ates years | 23andMe
our scale enables real time genetics health research research a | 23andMe
genome wide association studies | 23andMe
size and scale accelerate target discovery | 23andMe
hundreds of distinct clinical phenotypes across major and rare diseases i | 23andMe
genetic association of the signalling pathway with asthma | 23andMe
breadth of provides genetic understanding beyond single diseases | 23andMe
systematic scalable research platform yields novel drug targets | 23andMe
we have generated a research and development pipeline covering multiple therapeutic areas | 23andMe
targeting | 23andMe
our lead program was identified with and applied to our proprietary i genetic signature | 23andMe
and are negative regulators of axis combining inhibitors may enhance anti cancer activity | 23andMe
preclinical data supports combining with and inhibitors | 23andMe
phase study design for a high affinity antibody against | 23andMe
targeting a genetically validated approach to anti cancer therapy | 23andMe
me targeting | 23andMe
was identified as a promising anti cancer drug target with proprietary oncology i genetic signature | 23andMe
is an immune | 23andMe
me me binds with high affinity to and inhibits signaling me | 23andMe
phase study of me in patients with locally advanced or metastatic solid malignancies design objectives | 23andMe
me targeting a genetically validated approach to anti cancer therapy | 23andMe
| 23andMe
strong financial foundation to invest in future growth potential | 23andMe
strategic investments in future growth potential guidance updated net lose | 23andMe
income statement and guidance | 23andMe
revenue composition | 23andMe
consumer services revenue seasonality by quarter | 23andMe
research and development expense | 23andMe
sales and marketing expense composition | 23andMe
segment information and reconciliation of non financial measures | 23andMe
reconciliation of net income outlook to non adjusted outlook | 23andMe
we are redefining with data at scale coming soon | 23andMe
appendix | 23andMe
the vast majority of discoveries can be made without large scale sequencing | 23andMe
strategic collaboration with access to | 23andMe
value proposition | 23andMe
See More
23andMe
Investor Presentation Decks
Diagnostics & Research Decks
Healthcare Decks
Explore Topics
Cancer
Primary care
Recent decks by 23andMe
Investor Presentation
January 2024
Investor Presentation
April 2023
Investor Presentation
August 2022
Investor Day
January 2022
See all presentations by 23andMe (7 decks)
Related decks
AstraZeneca
Investor Conference
January 2024
Genprex
Investor Presentation
October 2022
AstraZeneca
Results
February 2021
BioNTech
Results
November 2020
Mainz Biomed NV
Investor Presentation
October 2023
RenovoRx
IPO
August 2021
Genelux
Investor Presentation
December 2023
Cano Health
Investor Presentation
May 2022
Recent decks by 23andMe
See all presentations (7 decks)
Investor Presentation
January 2024
Investor Presentation
April 2023
Investor Presentation
August 2022
Investor Day
January 2022
AstraZeneca
Investor Conference
January 2024
Genprex
Investor Presentation
October 2022
AstraZeneca
Results
February 2021
BioNTech
Results
November 2020
Mainz Biomed NV
Investor Presentation
October 2023
RenovoRx
IPO
August 2021
Genelux
Investor Presentation
December 2023
Cano Health
Investor Presentation
May 2022
Search Thousands of Presentations by World Leading Companies
Trending:
Addressable Market
Ecosystem
Beauty Market
WACC
NFT
Management Team
Investment Highlights

Stay in the loop

Join our mailing list to stay in the loop with updates and newest feature releases

Presentations

Start Up
IPO
SPAC
M&A
Investor Day
Results
ESG
Credit
Investment Banking

Explore

Presentation Collections
Slide Collections

Company

Blog
Contact us
© 2021-2023 Slidebook.io